To amend title 38, United States Code, to direct the Secretary of Veterans Affairs to furnish an opioid antagonist to a veteran without requiring a prescription or copayment.
Legislative Progress
Plain English Summary
AI-generatedPlain-English Summary
This bill would require the Department of Veterans Affairs (VA) to provide opioid antagonists — medications like naloxone (commonly known by the brand name Narcan) that can reverse a potentially fatal opioid overdose — directly to veterans without needing a prescription or charging a copayment. Currently, veterans may face barriers to obtaining these life-saving medications, such as needing a doctor's prescription or paying out-of-pocket costs. This bill would remove both of those obstacles for veterans seeking access to these drugs.
The bill would primarily affect veterans who use VA health care services, as well as their families and caregivers who may be in a position to administer an overdose-reversal medication in an emergency. Opioid antagonists work quickly to temporarily block the effects of opioids in the body, and having them readily available can be the difference between life and death during an overdose situation. By making these medications easier to obtain, the bill aims to increase the likelihood that veterans and those around them have the medication on hand if it is ever needed.
The bill has been introduced in the House of Representatives and referred to both the House Committee on Veterans' Affairs and its Subcommittee on Health, where a hearing has been held. It has not yet been voted on or passed into law. No official cost estimate or formal description has been provided for the legislation at this stage.
This summary is AI-generated for informational purposes. Always refer to the official bill text for legal accuracy.
Latest Action
Subcommittee Hearings Held
January 13, 2026
Sponsor
Committees
Legislative History
Subcommittee Hearings Held
Jan 13, 2026Referred to the Subcommittee on Health.
Nov 17, 2025Referred to the House Committee on Veterans' Affairs.
Nov 10, 2025Introduced in House
Nov 10, 2025Introduced in House
Nov 10, 2025